{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02022904",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Pro00037349"
      },
      "Organization": {
        "OrgFullName": "Duke University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology",
      "OfficialTitle": "Development of a Novel Method to Detect Prostate Cancer Circulating Tumor Cells (CTCs) Based on Epithelial-mesenchymal Transition Biology"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2015",
      "OverallStatus": "Withdrawn",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2012"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2015",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2015",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 18, 2013",
      "StudyFirstSubmitQCDate": "December 23, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 30, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 28, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 30, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Duke University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "United States Department of Defense",
            "CollaboratorClass": "FED"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a minimal risk correlative clinical blood-drawing protocol. The objective of this lead in pilot component is to determine whether Circulating Tumor Cells (CTC's) can be captured using the novel mesenchymal-marker based Near Infrared-Emissive Polymersomes (NIR-EPs), the PSMA-based NIR-EP, and the epithelial EpCAM-based NIR-EP. If successful, the capture method will be evaluated further in the larger comparative study."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Prostate Cancer"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "prostate cancer",
          "metastatic",
          "castrate resistant"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "0",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Metastatic prostate cancer",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Near infrared (NIR) emissive nanotechnology",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Device: Near infrared (NIR) emissive nanotechnology"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Device",
            "InterventionName": "Near infrared (NIR) emissive nanotechnology",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Metastatic prostate cancer"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in Non-detection rate of CTC's in men with CRPC",
            "PrimaryOutcomeDescription": "Non-detection rate of CTC's in men with CRPC will be measured at baseline, month 3, and at progression",
            "PrimaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Median number of CTC's detected by each capture method",
            "SecondaryOutcomeDescription": "Calculate for each patient the number of CTC's detected by each capture method (novel and standard).",
            "SecondaryOutcomeTimeFrame": "baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Change in median number of CTC's for each method",
            "SecondaryOutcomeDescription": "For each method, we will plot the change across time (baseline, cycle 3, and at progression) in the median number of CTC's for each method (novel and standard).",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with presenting clinical stage",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with sites of metastatic disease",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with Gleason sum",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with PSA kinetics",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with therapies",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with overall survival",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with progression-free survival",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Correlation of CTC enumeration with response to therapy",
            "SecondaryOutcomeTimeFrame": "at baseline, month 3, and progression (up to 18 months)"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nhistologically confirmed diagnosis of adenocarcinoma of the prostate\nClinical or radiographic evidence of metastatic disease\n\nEvidence of disease progression on androgen deprivation therapy (ADT) as evidenced by either of the following in the past:\n\nTwo consecutive PSA levels greater than the PSA nadir achieved on ADT, separated by greater than one week\nRadiographic evidence of disease progression as defined by new bone scan lesions or soft tissue/visceral metastases >2 cm in diameter.\nClinical progression as determined by the treating physician.\nAge greater than 18 years.\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nHistory of intercurrent or past medical or psychiatric illness that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s)",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Andrew Armstrong, MD",
            "OverallOfficialAffiliation": "Duke University",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022",
      "RemovedCountryList": {
        "RemovedCountry": [
          "United States"
        ]
      }
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011471",
            "ConditionMeshTerm": "Prostatic Neoplasms"
          },
          {
            "ConditionMeshId": "D000009360",
            "ConditionMeshTerm": "Neoplastic Cells, Circulating"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000005834",
            "ConditionAncestorTerm": "Genital Neoplasms, Male"
          },
          {
            "ConditionAncestorId": "D000014565",
            "ConditionAncestorTerm": "Urogenital Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000011469",
            "ConditionAncestorTerm": "Prostatic Diseases"
          },
          {
            "ConditionAncestorId": "D000009362",
            "ConditionAncestorTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M13487",
            "ConditionBrowseLeafName": "Prostatic Neoplasms",
            "ConditionBrowseLeafAsFound": "Prostate Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11457",
            "ConditionBrowseLeafName": "Neoplastic Cells, Circulating",
            "ConditionBrowseLeafAsFound": "Circulating Tumor Cells",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8098",
            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16467",
            "ConditionBrowseLeafName": "Urogenital Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13485",
            "ConditionBrowseLeafName": "Prostatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}